Tango Therapeutics reported trial results showing an 82% tumor response rate with its investigational regimen in combination with Revolution Medicines’ Rasonque for advanced pancreatic cancer. In the reported dataset, 88% of patients remained alive without tumor progression at nine months, and the study highlights the absence of chemotherapy in the regimen. The announcement positions the strategy as an example where targeted combinations may outperform single-agent approaches in tough-to-treat subtypes of pancreatic cancer. The readout was framed as bolstering a development path focused on better outcomes without traditional chemotherapy sequencing. The next steps for the field will likely center on confirmatory trials and on identifying the molecular or clinical factors that predict durable disease control within the responders.